Hart Blik . nl - Gezien vanuit het hart!
John Jacobs
  • John
    • Over mij
    • About me
  • COVID-19 overzicht
    • Covid is niet voorbij
    • Oversterfte in Europa
    • Groepsimmuniteit weer opnieuw bekeken >
      • ​1. Over groepsimmuniteit. Giwob
      • 2. Drie mislukte pogingen. GIwob
      • ​3. Bereken de kosten. GIwob
      • 4. Onvolledige immuniteit. Giwob
      • 5. Wat zou er mis kunnen gaan? GIwob
      • 6. Wat kunnen we doen? GIwob
      • 7. Kort & krachtig! GIwob
    • Simpel&complex
    • Viruscontrole
    • Meer negativiteit
    • Epidemie controle
    • 2jaar-COVID19
    • Humanitair
    • Vragen >
      • Vragen over ziekte
      • Vragen over vaccins
      • Vragen over immuniteit
      • Vragen over Epidemie
      • Vragen over mutaties
      • Vragen over politiek
    • Gezondheidsraad
    • VirusEthiek >
      • Effectief en open strijden
      • Gaan we voor het goede?
      • Ziektecijfers
      • Vaccinatie
      • Preventie besmettingen
    • Virusmutaties
    • Bijzondere immuniteit
    • infectie zonder ziekte
    • Onnavolgbaar beleid dat verkeerd uitpakt >
      • Hoe goed bestrijden we COVID-19 ?
      • Gevaarlijk
      • Stoppen
      • Zijn de vaccins goed?
      • Beschermen vaccins tegen infectie?
      • Maakte Nederland de juiste keuzes?
      • Achterkamertjes geheimen
      • Wat zou Nederland moeten gaan doen?
      • Kanttekeningen
    • Afweer en vaccin >
      • IFR
      • Immuunreacties
      • Verschillende vaccins
      • Studies en resultaten
      • Een vaccin en dan?
    • Vaccinatieplan
    • Epidemiebestrijding herzien >
      • Epidemiebestrijding herzien. Strategie
    • Test, traceer & isoleer
    • Palet aan testen
    • Besmetting voorkomen
    • Geen groepsimmuniteit
    • Geen vaccin
    • Ziekte COVID-19
    • Advies VWS
    • 1953 versus 2020
    • Onder de loep >
      • RIVM virus bestrijding
    • Dwalen op bekend terrein
    • Dashboard >
      • Dashboard. I
    • Humanitair
    • Foute afweer
    • Betere bestrijding van de epidemie >
      • Beter (A) Impact COVID-19
      • Beter (B) Tussen complot en kritiekloos
      • Beter (C) Verschillende strategieën
      • Beter (D) Vaccin of beter maken
    • Cijfers en data >
      • Mutations
    • Bestrijding COVID19
    • Mondkapjes
    • Model leren voor beter handelen >
      • Model leren voor beter handelen 3
      • Model leren voor beter handelen 4
      • Model leren voor beter handelen 5
      • Model leren voor beter handelen 6
      • Model leren voor beter handelen 7
    • Verloren door te weinig kennis
    • Ontelbaar op waarde geschat
    • Rekenen zonder getallen
    • Versimpeld model Corona NL >
      • Addendum. Correctie
      • Erratum
    • FAQ - COVID-19 >
      • FAQ. Epidemie
      • FAQ. Model
      • FAQ. Bestrijding
      • FAQ. Ziekte
      • FAQ. Coronavirussen
    • Reacties
    • Immuniteit en antistoffen >
      • Rekenen zonder getallen 7
      • Model leren voor beter handelen 2
    • Platform BZC
  • Medisch & biologie
    • Schepping & evolutie
    • Schepping verbeteren
    • Niet-sterieliserende slijmvlies immuniteit
    • Willem den Otter. In Memoriam
    • Luchtvervuiling doodt >
      • Luchtvervuiling doodt1
      • Luchtvervuiling doodt. 2
      • Luchtvervuiling doodt. 3.
      • Luchtvervuiling doodt. 4.
      • Luchtvervuiling doodt. 5.
    • Voorkom epidemie
    • Expert opinion
    • Ongezonde gezondheid
    • HPV
    • Ontsnappende virussen
    • Eiwit evolutie >
      • Afweer ontwerp
    • Tumor immunologie
    • Huidveiligheid
  • Samenleving
    • Schepping & evolutie
    • Schepping verbeteren
    • ORTEC blogs >
      • P4O2-COVID19
      • U-Prevent
      • Clinical decision support
      • Data voor betere patiëntenzorg
    • Licht & helderheid verschaffen.
    • AI summerschool (NL)
    • Racisme
    • Kwaadaardig complotten
    • Drie complotten
    • Bang
    • Onvrede en vrede
    • Schoppentroef
  • Federa
    • Federa deelnemers
  • English blogs
    • Covid is not over
    • ExcessMortalityEEA
    • Effective and open
    • Range of tests
    • SupplementEM
    • Virus Ethics >
      • Do we strife for the good things?
      • Disease outnumbered
      • Special immunity
      • Vaccination
      • Immune responses and vaccin >
        • Immune responses
        • Different vaccines
        • Trials and results
        • Next steps
        • Prevention of epidemic
        • Vaccinationwise
    • Non-sterile mucosal immunity
    • Contamination
    • No herd immunity >
      • Questions on COVID-19 >
        • Disease
        • Vaccine >
          • Immunity
        • Epidemics
        • Poltics
        • IFR
    • Test, trace & isolate
    • No vaccine
    • Disease
    • Lost at familiar property
    • Corona Dashboard
    • Fighting COVID19
  • ORTEC in English
    • P4O2-COVID19
    • Data science for better treatment of leukemia.
    • U-Prevent [EN]
    • Clinical decision support [EN]
    • Data to improve patient care
  • Linkpagina

COVID-19

Foto
Foto

Non-sterilising mucosal immunity

John Jacobs, 4th of January 2021. 

Foto

Many politicians are convinced that vaccination offers the best protection against coronaviruses. This is a dangerous oversimplification. Virology and immunology provide different lessons for epithelial tissues, that are beyond the tissues embedded in the blood circulation, e.g., the mucous membranes of the respiratory and the gastrointestinal tract. I hope to illustrate the essence of this wonderful field to non-experts in highly simplified pictures.

Many medical and social problems have a link to immunology, such as insight into evolution from immunology, animal experiments and alternatives, health damage from air pollution, therapy against cancer, vaccinations, and infections by bacteria and viruses. I would love to share my passion for this great subject, and provide some background for evidence-based policies. 

Course of infection and disease.

Figure 1 shows the course of SARS-2 infection on overall health and four organ systems in time. After the incubation period, the upper respiratory tract is infected. Local virus produced is the main source of contaminating and infecting other people. The virus will also spread to the gastrointestinal tract. Some patients will develop severe pneumonia. In the fourth stage, a subgroup may develop a life-threatening sepsis. This happens when the (neutralizing) antibodies are formed that prevent epithelial infection, but could facilitate infection in myeloid blood cells. I’ve hypothesized that these antibodies might contribute to the sudden worsening of COVID-19. Sepsis seems to be an obvious explanation for the acute phase with potentially fatal immune overactivation. People who recover first clear the virus from the upper airways and the lungs, later from the gastrointestinal tract and circulation.
Foto

Figure 1. Course of infection and disease.
​Horizontally:
A. Patient health.
B. Monthly calendar.
C. Upper respiratory tract disease, such as oro- and nasophrynx.
D. Gastrointestinal disease.
E. Lung disease.
F. Systemic illness and sepsis.
1 to 6 are the different stages in time.
​Red indicates virus replication in an organ system. Not every patient develops pneumonia, gastrointestinal infection and sepsis (see text).

No sterilizing immunity in airways.

Many virus infections cause herd immunity, but respiratory viruses rarely cause sterilising immunity. Sterilising immunity is a precondition for herd immunity, so I’ll zoom into the special mucosal immunity (Figure 2). In immune persons, the circulation carries antibodies (immunoglobulin G, IgG) and cellular immune cells to almost all tissues, except for the outermost layer of the skin and mucous membranes (Figure 2B). The antibodies and immune cells normally do not enter the outer epithelium, the most outer part, beyond the basement membrane zone (BMZ). This is called non-sterilising immunity.

In incipient infections, viruses multiply at the mucous zone, even though the host is immune (Figure 2C). Virus produced in the outermost layer of the upper respiratory epithelium is closest to the exit and can thus easily infect other people. Thus, someone with an infection and non-sterilising ​immunity can infect others. However, if the infection becomes more severe, the BMZ is partially broken down and the antibodies and the T cells flow in to clear the virus (Figure 2D).
Foto
A
Foto
B

Foto
C
Foto
D

Figure 2. Immunity in the epithelial tissues.
A
. Mucous membrane in a naive person.
B. Mucous membrane in an immune person. The mediators of immunity (antibodies and Tc) in the tissue are below the BMZ, but not above the BMZ.
C. Virus infection in an immune person can initially take place uninhibited on the outside of the BMZ.
D. If the virus infection becomes more serious, the basement membrane becomes permeable and the virus is efficiently cleared, preventing further infection.
BMZ = Basal membrane zone. Tc. Cytotoxic T cell. B = B cell. IgG = immunoglobulin G. Blue cells are dendritic cells that coordinate the immune system, green are the effector immune cells. Gray = normal tissue, green = immunity, red = virus and / or infected cell or tissue, yellow = healthy tissue.

Infection at non-sterilising immunity

People with non-sterilising ​immunity can become infected and thus contaminate and infect others, but they do not become ill from the pathogen (Figure 3). They will have a limited infection in the upper respiratory tract (C) and possibly the gastrointestinal tract (E). The vaccine studies did not study fecal virus, but the mechanisms of both mucosal immune systems are similar. In the lungs (D) and circulation (F), the antigen-specific immunity is fully active to protect immune persons against serious illness.
Foto

Figure 3. Course of infection and disease in non-sterilising immunity.
See figure 1 for explanation.
​

A special antibody.

Is it possible to become immune against viruses and bacteria in the mucous membranes? In the late 1940s, it was shown that antibodies first appear in blood and later in urine and feces. These antibodies were slightly different and called immunoglobulin A (IgA).
 
Antibodies in mucous membranes have been detected in a non-invasive bacterium, Vibrio cholerae, that does not enter the body and remains in the intestines. Cholera, however, is a life-threatening disease – with "rice water" diarrhea, as the cholera toxin dysregulates the intestines to spread these bacteria.
 
IgA could provide immunity in mucous membranes, such as the respiratory tract and gastrointestinal tract (Figure 4). What is special about IgA is that it is transported over the BMZ (Figure 4A) and clears the bacteria or viruses in the most outer tissues (Figure 4B). IgA is crucial for the mucosal immune system.
Foto
A
Foto
B

Figure 4. Mucosal immunity with IgA
​A. IgA Immunity.
B. Virus clearance in the mucosa by IgA.
Compare to Figure 2. IgA = immunoglobulin A.

Special Vaccines.

Developing vaccines that induce IgA is a major challenge. IgA is the last domain of the constant regions of antibodies. (Figure 5). This implies that it will take longer time for immune response to mature to IgA production, as was shown in the cholera infection. Evoking and maintaining IgA production is a major challenge for vaccines, but also crucial for some vaccines, like cholera. The cholera vaccine provides with 85% protection, early after vaccination, but falls to 50% within a year, and declines further thereafter.
Foto

Figure 4. Genomic organization of the antibody protein domains.
L are the light chains, D and J the connecting regions and C the constant (heavy) chains that determine the antibody type. In blue, these genes are in line for IgM (μ), IgD (δ), different forms of IgG (γ3, γ1, γ2b, γ2a), IgE (ε) and IgA (α). New combinations are made by genetic recombination in the nucleus, with the previous version disappearing. Thus, the sequence is IgM -> IgG isoforms -> IgE -> IgA. Steps can be skipped, but because of the recombination, never be reversed. IgM are the antibodies in the immune system, IgG isoforms the most common, IgE is part of allergy and IgA is for mucous membranes.
.

John Jacobs
04.01.2021 - NL 20.12.2020

Powered by Maak je eigen unieke website met aanpasbare sjablonen.